Summary

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

The global Glucagon Like Peptide-1 (GLP-1) Agonists market will reach xxx Million USD in 2019 with CAGR xx% 2019-2025. The main contents of the report including:

Global market size and forecast

Regional market size, production data and export & import

Key manufacturers profile, products & services, sales data of business

Global market size by Major Application

Global market size by Major Type

Key manufacturers are included based on company profile, sales data and product specifications etc.:

Novo Nordisk

AstraZeneca

Eli Lily

GSK

Sanofi

Bristol-Myers Squibb

Amylin

Major applications as follows:

Hospital

Pharmacy

Others

Major Type as follows:

Exenatied

Liraglutide

Lixisenatide

Albiglutide

Dulaglutide

Regional market size, production data and export & import:

Asia-Pacific

North America

Europe

South America

Middle East & Africa

Table of Contents
1 Global Market Overview
1.1 Scope of Statistics
1.1.1 Scope of Products
1.1.2 Scope of Manufacturers
1.1.3 Scope of Application
1.1.4 Scope of Type
1.1.5 Scope of Regions/Countries
1.2 Global Market Size
2 Regional Market
2.1 Regional Production
2.2 Regional Demand
2.3 Regional Trade
3 Key Manufacturers
3.1 Novo Nordisk
3.1.1 Company Information
3.1.2 Product & Services
3.1.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.1.4 Recent Development
3.2 AstraZeneca
3.2.1 Company Information
3.2.2 Product & Services
3.2.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.2.4 Recent Development
3.3 Eli Lily
3.3.1 Company Information
3.3.2 Product & Services
3.3.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.3.4 Recent Development
3.4 GSK
3.4.1 Company Information
3.4.2 Product & Services
3.4.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.4.4 Recent Development
3.5 Sanofi
3.5.1 Company Information
3.5.2 Product & Services
3.5.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.5.4 Recent Development
3.6 Bristol-Myers Squibb
3.6.1 Company Information
3.6.2 Product & Services
3.6.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.7 Amylin
3.7.1 Company Information
3.7.2 Product & Services
3.7.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
4 Major Application
4.1 Hospital
4.1.1 Overview
4.1.2 Hospital Market Size and Forecast
4.2 Pharmacy
4.2.1 Overview
4.2.2 Pharmacy Market Size and Forecast
4.3 Others
4.3.1 Overview
4.3.2 Others Market Size and Forecast
5 Market by Type
5.By Exenatied
5.1 Exenatied
5.1.1 Overview
5.1.2 Exenatied Market Size and Forecast
5.2 Liraglutide
5.2.1 Overview
5.2.2 Liraglutide Market Size and Forecast
5.3 Lixisenatide
5.3.1 Overview
5.3.2 Lixisenatide Market Size and Forecast
5.4 Albiglutide
5.4.1 Overview
5.4.2 Albiglutide Market Size and Forecast
5.5 Dulaglutide
5.5.1 Overview
5.5.2 Dulaglutide Market Size and Forecast
6 Price Overview
6.1 Price by Manufacturers
6.2 Price by Application
6.3 Price by Type
7 Conclusion